Shares of Allergan plc (NYSE:AGN) have received a consensus recommendation of “Hold” from the twenty-four brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, sixteen have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $179.84.
AGN has been the subject of a number of analyst reports. Leerink Swann lowered Allergan from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $217.00 to $188.00 in a research report on Thursday, July 18th. TheStreet upgraded Allergan from a “d+” rating to a “c” rating in a report on Friday, July 12th. Guggenheim lowered Allergan from a “buy” rating to a “neutral” rating in a report on Wednesday, August 7th. Royal Bank of Canada restated a “hold” rating and issued a $178.00 price objective on shares of Allergan in a report on Thursday, August 8th. Finally, Barclays upped their price objective on Allergan from $176.00 to $188.00 and gave the company an “equal weight” rating in a report on Wednesday, August 7th.
AGN stock traded down $1.07 during trading on Monday, reaching $173.93. 2,179,730 shares of the company’s stock were exchanged, compared to its average volume of 3,303,661. The company has a quick ratio of 0.91, a current ratio of 1.03 and a debt-to-equity ratio of 0.34. Allergan has a 1-year low of $114.27 and a 1-year high of $182.55. The company’s fifty day moving average price is $167.92 and its 200-day moving average price is $153.31. The firm has a market cap of $57.39 billion, a PE ratio of 10.42, a P/E/G ratio of 2.07 and a beta of 1.65.
Several institutional investors have recently made changes to their positions in AGN. Nuveen Asset Management LLC raised its position in shares of Allergan by 1,665.9% during the second quarter. Nuveen Asset Management LLC now owns 3,104,662 shares of the company’s stock worth $519,813,000 after purchasing an additional 2,928,846 shares during the period. Assenagon Asset Management S.A. raised its position in shares of Allergan by 415.5% during the third quarter. Assenagon Asset Management S.A. now owns 1,777,375 shares of the company’s stock worth $299,114,000 after purchasing an additional 1,432,555 shares during the period. Magnetar Financial LLC raised its position in shares of Allergan by 7,332.9% during the second quarter. Magnetar Financial LLC now owns 966,272 shares of the company’s stock worth $161,783,000 after purchasing an additional 953,272 shares during the period. OZ Management LP acquired a new stake in shares of Allergan during the second quarter worth $150,878,000. Finally, Paulson & CO. Inc. raised its position in shares of Allergan by 45.2% during the second quarter. Paulson & CO. Inc. now owns 2,249,500 shares of the company’s stock worth $376,634,000 after purchasing an additional 700,000 shares during the period. 80.52% of the stock is currently owned by institutional investors.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Further Reading: What is a stock buyback?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.